Septerna (NASDAQ:SEPN) Issues Quarterly Earnings Results

Septerna (NASDAQ:SEPN) posted its quarterly earnings data on Monday. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14, FiscalAI reports. The company had revenue of $26.75 million during the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%.

Septerna Price Performance

NASDAQ SEPN traded up $0.02 during trading on Monday, reaching $38.85. 275,434 shares of the company’s stock were exchanged, compared to its average volume of 346,877. The business has a 50 day moving average price of $34.40 and a 200-day moving average price of $29.02. The stock has a market capitalization of $1.75 billion, a P/E ratio of -47.96 and a beta of 2.29. Septerna has a fifty-two week low of $10.62 and a fifty-two week high of $40.65.

Insider Buying and Selling

In related news, insider Samira Shaikhly sold 2,178 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider owned 793 shares in the company, valued at approximately $27,897.74. This represents a 73.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel D. Long sold 3,334 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $34.47, for a total value of $114,922.98. Following the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,323,321.64. This represents a 3.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 47,828 shares of company stock valued at $1,584,314. Insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

Several institutional investors and hedge funds have recently modified their holdings of the stock. Woodline Partners LP lifted its stake in shares of Septerna by 94.2% during the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock worth $3,373,000 after buying an additional 282,585 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after buying an additional 3,323 shares during the period. Geode Capital Management LLC grew its stake in Septerna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after buying an additional 78,316 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after buying an additional 1,315 shares during the last quarter. Finally, CW Advisors LLC bought a new position in Septerna in the 2nd quarter valued at about $133,000.

Wall Street Analysts Forecast Growth

SEPN has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Stifel Nicolaus initiated coverage on Septerna in a research note on Friday, May 1st. They set a “buy” rating and a $43.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Septerna in a report on Wednesday, July 1st. Guggenheim decreased their target price on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, July 1st. Finally, Raymond James Financial boosted their target price on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.89.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.